- Login
- Manage Portfolio
- Post a StockTalk
- Write an Instablog
- Get Daily Email Alert
-
Seeking Alpha
Sort by:
Latest
|
Editors' Picks
|
Most Commented
|
Most Popular
-
Mentor Capital Cancer Vaccine Investing Update
-
Many Reasons to Launch a Global Generic Drug ETF
-
Mentor Capital Plans 2010 Launch of Cancer Vaccine Active Index Fund
-
NeoStem: Start of a New Era
-
Extreme FDA Trades: 30 Stocks Under 5 Bucks
-
Healthcare ETFs Are Outpacing the Market
-
Cytori Therapeutics: Natural Celution for Breast Reconstruction
-
32 Stem Cell Companies to Watch
-
Access Pharma: CEO Interview and Update
-
Diabetes Care: Global Investing Opportunities
-
BioMed News Bytes: GeoVax, Cerus, Discovery Labs, NeurogesX
-
BioMed News Bytes: Cytori, Poniard, Alkermes, Spherix, CRXX, HGSI
-
Top 10 Emerging Biotech Stocks
-
ImmunoCellular's Promising Brain Cancer Vaccine
-
Under the Radar Healthcare Stocks: Protox, Pressure BioSciences, Unilife
-
BioMed News Bytes: Transcept, ProUroCare, SciClone, ABIO
-
Stem Cell and Regenerative Medicine Stocks Surge in December
-
Nothing Generic About this Growth Industry
-
FDA Calendar Extreme Trades: 85 Single Digit Stocks
-
My Top Four Emerging Micro-Cap Biotech Stocks
-
Railroad Stocks Steam Ahead on Buffett’s Buy of BNI
-
BioMed Updates: Merck KGaA, BioMarin, Cytori and Theravance
-
Small Cap Stocks Battling Brain Cancer
-
FDA Calendar Updates: Transcept Pharma Surges on Deal
-
BioMed News Bytes: Progenics, Somanetics, Ziopharm, Cardium, pSivida, BioMimetic Therapeutics
-
Momenta Pharma's M-Enoxaparin: Timing Uncertain, Approval Likely
-
Healthcare: Investing Trends for 2009
-
Pending FDA Decisions: 12 Extreme Trades
-
Upcoming FDA Decisions and Clinical Trials: Prevacid Goes OTC, Swine Flu Test
-
A Super(Gen) Play on Cancer Biotech Consolidation
-
Celldex Therapeutics: Plenty of Cash, Pending Clinical Catalysts
-
Pending FDA Decisions: 20 Extreme Trades
Latest Comments on Mike Havrilla's Articles